MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
Key Highlights
- ➤LensAI screened 890,634 antibody sequences in 4 hours and 41 minutes
- ➤Amazon EC2 Hpc8a delivered 37% faster performance than comparable Intel configuration
- ➤Hpc8a reduced cost per sequence approximately 43% versus comparable Intel configuration
- ➤LensAI screened PLAbDab’s 348,550 sequences in 2 hours and 12 minutes
- ➤LensAI classified 197 of 217 therapeutic antibodies as above 30% incidence risk
Expert Statements
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Every antibody drug carries a question: will the patient’s own immune system attack it”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Answering that question late is one of the most expensive failures in this industry.”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Answering it early has been impractical, because AI now designs candidates far faster than anyone could screen them.”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“This work shows LensAI screening all of them.”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Candidate selection and safety assessment are no longer the bottleneck.”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“It also lowers what it costs us to deliver at this scale, so we can take on more volume without our costs rising in step with it.”
Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk
“Our work with AMD now spans their accelerators and server CPUs”
Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk
“That gives us a compute foundation that can scale with the complexity and volume of modern drug discovery.”
Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk
“Just as importantly, we can continue taking advantage of advances in AMD EPYC processors without having to rewrite the underlying LensAI code.”
MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
New white paper shows LensAI™ immunogenicity screening running at up to 43% lower cost per sequence on Amazon EC2 Hpc8a instances powered by AMD EPYC processors, making a critical drug-safety check practical at the scale AI-driven discovery now demands
Get started
Create a free account to read the full story.